Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Banting Postdoctoral Fellowship Program

Direct Payment

$140,000.00

In vivo prime editing to rescue autosomal dominant retinitis pigmentosa

EF 2024-25

Résumé
Retinitis pigmentosa is the leading cause of visual disability and blindness in people under 60 years old, including for Canadians. Retinitis pigmentosa is a genetic disease, caused by a DNA mutation inherited from one parent or both parents, and leads to degeneration of the retina; vision loss is progressive and typically begins in childhood or adolescence. However, despite over a century of evaluating potential therapies, no treatments are available for most causes of retinitis pigmentosa, including the most prevalent dominantly inherited DNA mutation causing retinitis pigmentosa, known as RHO-P23H. Here, we will develop prime editing, a powerful new tool to edit DNA, to correct the RHO-P23H mutation and rescue retinitis pigmentosa. To do so, we will optimize the efficiency and precision of RHO-P23H prime editing, demonstrating permanent RHO-P23H correction in isolated patient cells in a dish. Upon identification of a promising strategy, we will assess the treatment effects of corrective prime editing via a single injection in the "gold-standard" pig model of RHO-P23H retinitis pigmentosa, including evaluations of the rescue of retina structure, retina function, and vision loss. Preliminary experiments have shown promise, as we have demonstrated the feasibility of using prime editing to correct RHO-P23H in patient cells as well as demonstrated significant treatment effects in the pig model of disease. The proposed work potentiates a one-time, one-injection treatment for a major genetic cause of visual disability and blindness, for Canadians and people throughout the world. Moreover, the successful completion of this project represents a seminal milestone in the advancement of editing DNA to treat human disease, paving the way for the wider development of treatments for currently untreatable genetic diseases.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
511910
Name
Chen Paul Z
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
In vivo prime editing to rescue autosomal dominant retinitis pigmentosa
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Crispr; Genetic Disease; Genetic Medicine; Genome Editing; Large-Animal Model Of Disease; Prime Editing; Retinitis Pigmentosa; Rhodopsin; Vision Loss
Abstract
Retinitis pigmentosa is the leading cause of visual disability and blindness in people under 60 years old, including for Canadians. Retinitis pigmentosa is a genetic disease, caused by a DNA mutation inherited from one parent or both parents, and leads to degeneration of the retina; vision loss is progressive and typically begins in childhood or adolescence. However, despite over a century of evaluating potential therapies, no treatments are available for most causes of retinitis pigmentosa, including the most prevalent dominantly inherited DNA mutation causing retinitis pigmentosa, known as RHO-P23H. Here, we will develop prime editing, a powerful new tool to edit DNA, to correct the RHO-P23H mutation and rescue retinitis pigmentosa. To do so, we will optimize the efficiency and precision of RHO-P23H prime editing, demonstrating permanent RHO-P23H correction in isolated patient cells in a dish. Upon identification of a promising strategy, we will assess the treatment effects of corrective prime editing via a single injection in the "gold-standard" pig model of RHO-P23H retinitis pigmentosa, including evaluations of the rescue of retina structure, retina function, and vision loss. Preliminary experiments have shown promise, as we have demonstrated the feasibility of using prime editing to correct RHO-P23H in patient cells as well as demonstrated significant treatment effects in the pig model of disease. The proposed work potentiates a one-time, one-injection treatment for a major genetic cause of visual disability and blindness, for Canadians and people throughout the world. Moreover, the successful completion of this project represents a seminal milestone in the advancement of editing DNA to treat human disease, paving the way for the wider development of treatments for currently untreatable genetic diseases.
Competitiondate
202409
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Chen, Paul Z
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~